Drugs /

uv1 telomerase peptide vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.

Clinical Trials

View Clinical Trials for uv1 telomerase peptide vaccine

Uv1 telomerase peptide vaccine has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating uv1 telomerase peptide vaccine, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

Melanoma is the most common disease being investigated in uv1 telomerase peptide vaccine clinical trials [2].

Drug Details

Synonyms [2]:
epi7386, epi-7386, epi 7386, uv1/htert peptide vaccine
Drug Target(s) [2]:
TERT
NCIT ID [1]:
C104747

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.